Cabozantinib en el algoritmo terapéutico del cáncer renal metastásico. Ensayo Meteor - page 22

Cabozantinib

Sunitinib

Reducción de dosis:

46 (58%)

38 (49%)

Discontinuación:

16 (20%)

16 (21%)

Todos efectos adversos:

99%

Grado III-IV efectos adversos: 67%

68%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,12,13,14,15,16,17,18,19,20,21 23,24